Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Recommendation of “Hold” from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has received a consensus rating of “Hold” from the nine analysts that are currently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $10.00.

ZNTL has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Guggenheim lowered their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th.

Zentalis Pharmaceuticals Stock Down 4.6 %

ZNTL stock opened at $2.92 on Tuesday. The stock’s 50 day moving average is $3.34 and its two-hundred day moving average is $3.64. Zentalis Pharmaceuticals has a 52-week low of $2.66 and a 52-week high of $18.07. The company has a market capitalization of $208.09 million, a PE ratio of -1.17 and a beta of 1.84.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.36. As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Decheng Capital LLC boosted its position in shares of Zentalis Pharmaceuticals by 46.2% during the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock worth $12,558,000 after buying an additional 970,859 shares during the period. Verition Fund Management LLC boosted its position in Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after acquiring an additional 951,500 shares during the period. Primecap Management Co. CA grew its stake in shares of Zentalis Pharmaceuticals by 21.6% in the third quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock worth $5,513,000 after purchasing an additional 265,690 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Zentalis Pharmaceuticals by 152.6% during the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after purchasing an additional 399,745 shares during the period. Finally, GSA Capital Partners LLP raised its stake in shares of Zentalis Pharmaceuticals by 138.5% during the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after purchasing an additional 353,384 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.